📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Gland Pharma Q3 FY26: Adj. PAT Surges 37% YoY to ₹2,797 Mn; Revenue Up 22%
Gland Pharma delivered a strong performance in Q3 FY26, with consolidated revenue growing 22% YoY to ₹16,954 Mn. The company's Adjusted PAT saw a significant jump of 37% YoY to ₹2,797 Mn, supported by a recovery in margins. Adjusted EBITDA margins improved to 26% from 23% in the previous quarter, reflecting better operational efficiency. The core base business remains the primary driver, contributing ₹11,790 Mn to revenue with a healthy 28% PAT margin.
Key Highlights
Consolidated Revenue from operations grew 22% YoY and 14% QoQ to ₹16,954 Mn
Adjusted PAT increased 37% YoY to ₹2,797 Mn, with a sharp 52% sequential growth
Adjusted EBITDA margin expanded to 26% in Q3 FY26 from 23% in Q2 FY26
Base business revenue grew 16% YoY to ₹11,790 Mn with an Adjusted PAT of ₹3,274 Mn
R&D expenditure for the base business stood at ₹650 Mn, accounting for 5.5% of its revenue
💼 Action for Investors
The strong double-digit growth in both top-line and bottom-line suggests a robust recovery in the injectable segment. Investors should maintain a positive outlook given the margin expansion and steady performance of the core business.
Gland Pharma Q3 Revenue Jumps 22.5% YoY to ₹16,954 Million; Profitability Improves
Gland Pharma reported a strong performance for the quarter ended December 31, 2025, with consolidated revenue from operations growing 22.5% year-on-year to ₹16,953.63 million. Sequentially, revenue increased by 14% from ₹14,868.75 million in the previous quarter, indicating robust business momentum. Profit before tax for the quarter stood at ₹3,864.74 million, showing resilience despite a rise in employee benefit expenses and material costs. The company also confirmed the reappointment of Grant Thornton Bharat LLP as internal auditors for the upcoming financial year.
Key Highlights
Consolidated revenue from operations rose 22.5% YoY to ₹16,953.63 million in Q3 FY26.
Quarter-on-quarter revenue growth was robust at 14% compared to ₹14,868.75 million in Q2 FY26.
Total income for the nine-month period ended Dec 2025 reached ₹48,927.22 million versus ₹43,611.74 million YoY.
Profit before tax for the quarter was ₹3,864.74 million, maintaining healthy operational margins.
Grant Thornton Bharat LLP reappointed as Internal Auditors for the financial year 2026-27.
💼 Action for Investors
The strong double-digit growth in revenue both YoY and QoQ suggests a recovery in core markets and effective scale-up. Investors should maintain a positive outlook while monitoring the impact of rising operational costs on net margins.